We use our technology innovations, platforms and processes to advance a pipeline of therapeutic agents designed to modulate the cancer immunity cycle through multiple targets and mechanisms, as well as to approach a range of high value targets across disease indications other than cancer.
Targets
Discovery
Optimization
Development
Phase 1
Targets
Myeloid DCs
Targets
Discovery
Optimization
Development
Phase 1
Targets
Checkpoint Targets
Targets
Discovery
Optimization
Development
Phase 1
Targets
T & NK cells
Targets
Discovery
Optimization
Development
Phase 1
Targets
TME Targets
Targets
Discovery
Optimization
Development
Phase 1
Targets
Immune and other cell types
Targets
Discovery
Optimization
Development
Phase 1
Each dot on an arrow represents a distinct A-Kine program. Each A-Kine is unique in its mechanism of action
Our A-Kine programs incorporate interferon (IFN), interleukin (IL) and tumor necrosis factor (TNF) cytokine families and have been engineered to selectively interact with targets indicated in the left column. Our approach leverages proprietary molecular scaffold and linker frameworks, combined with targeting and cytokine effector modules, to create a diversity of agents, each with unique properties.
Allo-Glue programs are primarily focused on cancer and immunology targets, and in partnerships with Novartis and Genentech we are advancing discovery of multiple classes of glues for a range of targets across multiple therapeutic areas (not shown).
Clinical program: ORB-011
ORB-011 is a clinical-stage, targeted interferon that is designed to specifically activate cDC1 dendritic cells, immune cells that are specialized in presenting tumor antigens to, and activating, tumor cytotoxic CD8 T cells. It achieves localized activity by a unique mechanism of induced proximity on the cell surface of cDC1s. Orionis is evaluating ORB-011 in a Phase 1 open-label dose-escalation study (NCT05947474) for patients with recurrent or refractory solid tumors amenable to medically safe serial biopsies. The Phase 1 clinical trial will provide initial safety, pharmacokinetic and pharmacodynamic readouts, and identify a dose of ORB-011 for use in future studies. It is being conducted at this time at the M.D. Anderson Cancer Center in Houston, Texas and at Honor Health Research Institute in Scottsdale, Arizona.